369652-04-0 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl) is utilized as a research compound for its role as a selective serotonin reuptake inhibitor (SSRI), which aids in the development of medications targeting psychiatric and neurological disorders. Its ability to modulate serotonin levels makes it a valuable tool in studying neurotransmitter systems and in creating new therapeutic agents.
Used in Studying Neurotransmitter Systems:
In the field of neuroscience, 2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl) serves as a key substance for investigating the mechanisms of serotonin reuptake, which is crucial for understanding mood regulation and the pathophysiology of various mood disorders.
Used in Development of Medications for Psychiatric and Neurological Disorders:
2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl) is employed as a precursor in the synthesis of potential therapeutic agents for the treatment of psychiatric and neurological conditions, leveraging its SSRI properties to alleviate symptoms associated with these disorders.
Used in Psychopharmacology:
2-(1-phenyl-1H-pyrazol-4-yl)ethanamine(SALTDATA: HCl) is also explored in psychopharmacology for its potential psychoactive effects, providing insights into the development of substances that could influence cognitive and emotional processes.
Check Digit Verification of cas no
The CAS Registry Mumber 369652-04-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,9,6,5 and 2 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 369652-04:
(8*3)+(7*6)+(6*9)+(5*6)+(4*5)+(3*2)+(2*0)+(1*4)=180
180 % 10 = 0
So 369652-04-0 is a valid CAS Registry Number.
369652-04-0Relevant articles and documents
Synthesis and 5-HT2A antagonist activity of derivatives of the novel heterocycles indolo[3,2-d]pyrrolo[3,2-g]azecine and benzo[d]pyrrolo[3,2-g]azecine compared to the benz[d]indolo[2,3-g]azecine derivative LE 300
Rostom, Sherif A. F.,Farghaly, Ahmed M.,Soliman, Farid S. G.,El-Semary, Mona M.,Elz, Sigurd,Lehmann, Jochen
, p. 241 - 247 (2007/10/03)
An indolo[3,2-d]pyrrolo[3,2-g]azecine and a benzo[d]pyrrolo[3,2-g]azecine analogue of the potent dopamine receptor antagonist LE 300 (7-methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine) have been prepared in multi-step reactions via C-N bond cleavage of corresponding quaternary N-methylquinolizinium iodides. LE 300, the target compounds and two precursor quinolizines have been tested in vitro for antagonist activity at 5-HT2A receptors (rat tail artery) and H1 receptors (guinea-pig ileum), respectively. LE 300 and compound 19 (3,6-dimethyl-4, 5,6,7,8,13-hexahydro-3H-benzo[d]pyrrolo[3,2-g]azecine) competitively inhibited 5-HT-induced contractions with similar nanomolar potency (pA2 = 8.32 and 8.01, respectively) but were less active than the reference antagonist ketanserin (pA2 = 9.55). Compound 19 displayed moderate H1-antihistaminic activity in the guinea-pig ileum assay (pA2 = 7.37).
